Dr Mike Trower
Co-founder & Chief Scientific Officer
Mike is Co-founder and Chief Scientific Officer of KaNDy Therapeutics. It was Mike’s advocacy of the dual mechanism neurokinin-1,3 receptor antagonism, offered by NT-814, to present a novel and potentially transformational non-hormonal therapy for treatment of symptoms of the menopause and other related Women’s Health conditions which led to NT-814 being spun out of NeRRe Therapeutics to create KaNDy Therapeutics in 2017.
Mike has broad knowledge of neurokinin receptor biology and, in particular, the emerging science that has established the pivotal role these systems play in neuroendocrinology and female sex-hormone related disorders. Mike is also Co-founder and CSO of NeRRe Therapeutics whose focus is on developing the neurokinin-1 receptor antagonist orvepitant to treat neuronal hypersensitivity disorders including chronic refractory cough.
Prior to founding NeRRe, Mike worked in pharmaceutical industry R&D at GSK for nearly 20 years, where latterly he was VP & Head of the External Drug Discovery Group in the Neurosciences Centre for Excellence for Drug Discovery (CEDD). In this position, Mike successfully implemented the CEDD externalisation strategy and advanced a portfolio of preclinical and clinical pipeline assets.
Mike has BSc (Hons) and PhD degrees in biological sciences and has held post-doctoral positions at DuPont Inc in Delaware, US, and at the Medical Research Council in Cambridge, UK, under the Nobel laureate Professor Sydney Brenner.